Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Share-based Compensation (2016 - 2025)

Ligand Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $14.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 89.66% year-over-year to $14.3 million; the TTM value through Dec 2025 reached $46.8 million, up 14.02%, while the annual FY2025 figure was $46.8 million, 14.02% up from the prior year.
  • Share-based Compensation for Q4 2025 was $14.3 million at Ligand Pharmaceuticals, down from $14.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $29.1 million in Q4 2022 and bottomed at $5.7 million in Q4 2023.
  • The 5-year median for Share-based Compensation is $9.6 million (2021), against an average of $10.6 million.
  • The largest annual shift saw Share-based Compensation soared 180.02% in 2022 before it plummeted 80.37% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $10.4 million in 2021, then soared by 180.02% to $29.1 million in 2022, then tumbled by 80.37% to $5.7 million in 2023, then surged by 31.52% to $7.5 million in 2024, then skyrocketed by 89.66% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Share-based Compensation are $14.3 million (Q4 2025), $14.7 million (Q3 2025), and $10.0 million (Q2 2025).